164 related articles for article (PubMed ID: 25187266)
1. Dermatological side-effects in hepatitis C infected patients under a triple regimen associating pegylated interferon, ribavirin and telaprevir.
Bernardeschi C; Valeyrie-Allanore L; Ortonne N; Gressier L; Wallet-Faber N; Bernard PH; Hezode C; Duclos-Vallée JC; Samuel D; Mallet V; Pol S; Milpied B; Dupin N
J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):143-6. PubMed ID: 25187266
[No Abstract] [Full Text] [Related]
2. Severe renal impairment during triple therapy with telaprevir.
Carrier P; Chambaraud T; Vong C; Guillaudeau A; Debette-Gratien M; Jacques J; Legros R; Sautereau D; Essig M; Loustaud-Ratti V
Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):e69-71. PubMed ID: 24461554
[No Abstract] [Full Text] [Related]
3. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
Cacoub P; Bourlière M; Lübbe J; Dupin N; Buggisch P; Dusheiko G; Hézode C; Picard O; Pujol R; Segaert S; Thio B; Roujeau JC
J Hepatol; 2012 Feb; 56(2):455-63. PubMed ID: 21884670
[TBL] [Abstract][Full Text] [Related]
4. Side effects. Safety and effectiveness of interferon and ribavirin in HIV+ people co-infected with hepatitis C virus.
TreatmentUpdate; 2001; 12(8):4-5. PubMed ID: 12132439
[No Abstract] [Full Text] [Related]
5. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Oshita M; Mita E; Ito T; Inui Y; Inada M; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
J Viral Hepat; 2015 Mar; 22(3):254-62. PubMed ID: 25081140
[TBL] [Abstract][Full Text] [Related]
6. [Severe bone marrow aplasia due to triple therapy for hepatitis C virus infection: Apropos of a case].
Bautista Galán C; Serrato AR; Albandea Moreno C; Ruiz Arredondo J
Gastroenterol Hepatol; 2015 Nov; 38(9):542-3. PubMed ID: 25835261
[No Abstract] [Full Text] [Related]
7. Telaprevir-induced pityriasis rubra pilaris-like drug eruption.
Stalling SS; Vu JR; English JC
Arch Dermatol; 2012 Oct; 148(10):1215-7. PubMed ID: 23069976
[No Abstract] [Full Text] [Related]
8. [Antiviral therapy of hepatitis C].
Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.
Werner CR; Franz C; Egetemeyr DP; Janke-Maier P; Malek NP; Lauer UM; Berg CP
J Viral Hepat; 2014 May; 21(5):333-40. PubMed ID: 24716636
[TBL] [Abstract][Full Text] [Related]
10. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
[TBL] [Abstract][Full Text] [Related]
11. [Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].
Crespo G; Lens S
Gastroenterol Hepatol; 2012 May; 35(5):337-43. PubMed ID: 22349607
[TBL] [Abstract][Full Text] [Related]
12. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
Virolés Torrent S; López Nuñez C; Hombrados Verde M; Figa Francesch M; Ferri Iglesias MJ; Louvriex Freire R; Acero Fernández D
Gastroenterol Hepatol; 2015 Feb; 38(2):78-81. PubMed ID: 24948444
[No Abstract] [Full Text] [Related]
13. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.
Kumar KS; Russo MW; Borczuk AC; Brown M; Esposito SP; Lobritto SJ; Jacobson IM; Brown RS
Am J Gastroenterol; 2002 Sep; 97(9):2432-40. PubMed ID: 12358269
[TBL] [Abstract][Full Text] [Related]
14. Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.
Lens S; Calleja JL; Campillo A; Carrión JA; Broquetas T; Perello C; de la Revilla J; Mariño Z; Londoño MC; Sánchez-Tapias JM; Urbano-Ispizua Á; Forns X
World J Gastroenterol; 2015 May; 21(17):5421-6. PubMed ID: 25954117
[TBL] [Abstract][Full Text] [Related]
15. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
Sidhu-Malik NK; Kaplan AL
J Drugs Dermatol; 2003 Oct; 2(5):570-3. PubMed ID: 14558408
[TBL] [Abstract][Full Text] [Related]
16. Telaprevir-related dermatitis.
Roujeau JC; Mockenhaupt M; Tahan SR; Henshaw J; Martin EC; Harding M; van Baelen B; Bengtsson L; Singhal P; Kauffman RS; Stern RS
JAMA Dermatol; 2013 Feb; 149(2):152-8. PubMed ID: 23560295
[TBL] [Abstract][Full Text] [Related]
17. Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan.
Torii H; Sueki H; Kumada H; Sakurai Y; Aoki K; Yamada I; Ohtsuki M
J Dermatol; 2013 Aug; 40(8):587-95. PubMed ID: 23734933
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in hemodialysed patients.
Kaya S; Aksoz S; Baysal B; Ay N; Danis R
Infect Dis (Lond); 2015 Sep; 47(9):658-61. PubMed ID: 25936530
[TBL] [Abstract][Full Text] [Related]
19. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
20. High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.
Cachay ER; Wyles DL; Torriani FJ; Ballard C; Colwell B; Lin JC; Hill L; Mathews WC
AIDS; 2013 Nov; 27(18):2893-7. PubMed ID: 23842130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
